Biotechnology News and Research

RSS

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Instem, a leading provider of early drug development software solutions, announced today that Integrated Laboratory Systems (ILS) has subscribed to Provantis™ Online, enhancing their existing software systems.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

It Starts with the Heart: Community initiative launched to support not-for-profits of all sizes

Health Diagnostic Laboratory Inc., www.hdlabinc.com, has launched a community initiative known as It Starts with the Heart, a company-wide commitment to support not-for-profits of all sizes in making a difference in their community.

6 Mar 2010

AMICAS and Merge Healthcare sign definitive merger agreement

AMICAS, Inc. and Merge Healthcare Incorporated (Nasdaq: MRGE) today announced that they will enter into a definitive merger agreement pursuant to which Merge will acquire all of the outstanding shares of AMICAS for $6.05 per share in cash, or an aggregate of $248 million.

5 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

China Pharma Holdings reports 21% increase in 2009 revenue

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the fiscal year ended December 31, 2009.

5 Mar 2010

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

An article in the Glencoe Enterprise recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

5 Mar 2010

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

5 Mar 2010

Tax treaty with U.S. will pave way for investment in Canadian biotechnology firms, says BIOTECanada

Removing administrative barriers under the Canada-US Tax Treaty for investors such as non-resident venture capital funds are a welcome change, and ease the way for investment in Canadian biotechnology firms according to trade industry association BIOTECanada.

5 Mar 2010

Endothelial cells can produce copious amounts of adult stem cells: Study

In a leap toward making stem cell therapy widely available, researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College have discovered that endothelial cells, the most basic building blocks of the vascular system, produce growth factors that can grow copious amounts of adult stem cells and their progeny over the course of weeks.

5 Mar 2010

Patient enrollment in Phase II study of BioCart Autologous Cartilage System nearing halfway point

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality-of-life for sufferers of articular cartilage injuries, today announced that patient enrollment in the Company’s Phase II study of the BioCart™ Autologous Cartilage System is nearing the halfway point and is expected to be completed within the next three months.

5 Mar 2010

Combating liver fluke: Queen's University Belfast heads international research effort

Queen's University Belfast is spearheading a £1 million international research effort to combat liver fluke - a parasite which causes disease in livestock, resulting in billions of pounds in losses every year to farmers around the world.

5 Mar 2010

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Kyto Biopharma Inc., is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York. The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.

5 Mar 2010

Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.

4 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

BioMS Medical invests in Spectral Diagnostics securities

BioMS Medical Corp. acquired pursuant to a private placement of units, beneficial ownership and control over 30,000,000 common shares and 15,000,000 common shares purchase warrants of Spectral Diagnostics Inc..

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

Biotechnology News and Research

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

It Starts with the Heart: Community initiative launched to support not-for-profits of all sizes

AMICAS and Merge Healthcare sign definitive merger agreement

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

China Pharma Holdings reports 21% increase in 2009 revenue

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Tax treaty with U.S. will pave way for investment in Canadian biotechnology firms, says BIOTECanada

Endothelial cells can produce copious amounts of adult stem cells: Study

Patient enrollment in Phase II study of BioCart Autologous Cartilage System nearing halfway point

Combating liver fluke: Queen's University Belfast heads international research effort

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

BioMS Medical invests in Spectral Diagnostics securities

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News